Pricing Log in Create free account

Axsome Therapeutics, Inc. (AXSM) vs Spyre Therapeutics, Inc. (SYRE)

Axsome Therapeutics, Inc. and Spyre Therapeutics, Inc. are both Biotechnology companies. Axsome Therapeutics, Inc. is the larger, with a market value of $8.5B against $7.4B — 1.1× the size. Axsome Therapeutics, Inc. grew revenue faster over the last twelve months: 56.9% against −81.8%. Spyre Therapeutics, Inc. has the higher net margin (0.00% vs −24.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Spyre Therapeutics, Inc. leads on 10 and Axsome Therapeutics, Inc. on 6.

Valuation

Metric AXSM SYRE Biotechnology median
P/E n/m n/m 8.50
P/S 10.48 6,423.00 9.71
P/B 97.71 7.09 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 10.23 5,336.34 9.21
Earnings yield (2.39%) (2.67%) (33.15%)
Free cash flow yield (0.88%) (3.08%) (25.50%)

Profitability

Metric AXSM SYRE Biotechnology median
Gross margin 93.24% 100.00% 65.16%
Operating margin (23.96%) 0.00% 0.00%
Net margin (24.68%) 0.00% 0.00%
Free cash flow margin (9.27%) 0.00% 0.00%
Return on equity (245.10%) (28.52%) (56.36%)
Return on assets (27.35%) (20.90%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AXSM SYRE Biotechnology median
Revenue growth (TTM) 56.87% (81.84%) 6.02%
EPS growth (last fiscal year) 38.56% 55.24% 30.26%
Revenue growth, 5-year CAGR — (28.15%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AXSM SYRE Biotechnology median
Debt to equity 1.52 0.00 0.00
Current ratio 1.43 18.53 4.72
Net debt to EBITDA 1.29 3.61 0.96

Dividend

Metric AXSM SYRE Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric AXSM SYRE Biotechnology median
Market cap 8.47b 7.39b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack